Background and Aims NAFLD is characterized by insulin resistance and dysregulated lipid
and glucose metabolism. Saroglitazar, a dual peroxisome proliferator activated receptor‐α/γ …

Nonalcoholic fatty liver disease (NAFLD) is a burgeoning health problem worldwide and an
important risk factor for both hepatic and cardiometabolic mortality. The rapidly increasing …

Nonalcoholic fatty liver disease (NAFLD) has become the most prevalent cause of liver
disease, increasingly contributing to the burden of liver transplantation. In search for …

Background. Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic
liver disease. Patients with non-alcoholic steatohepatitis (NASH) have increased plasmatic …

Nonalcoholic fatty liver disease (NAFLD) is initiated by excessive fat buildup in the liver,
affecting around 35% of the world population. Various circumstances contribute to the …

Nonalcoholic fatty liver disease (NAFLD) is a frequent and potentially progressive chronic
liver disease that occurs in subjects who do not abuse alcohol. NAFLD is often associated …

Cholestasis, including primary biliary cirrhosis (PBC) and primary sclerosing cholangitis
(PSC), results from an impairment or disruption of bile production and causes intracellular …

Objective Peroxisome proliferator-activated receptor α (PPARα) is a nuclear receptor
expressed in tissues with high oxidative activity that plays a central role in metabolism. In …

NASH is within the spectrum of NAFLD, a liver condition encompassing liver steatosis,
inflammation, hepatocyte injury, and fibrosis. The prevalence of NASH-induced cirrhosis is …

Non-alcoholic fatty liver disease (NAFLD) is to date the most common chronic liver disease
in clinical practice and, consequently, a major health problem worldwide. It affects …